Cytokine-based immunotherapy has disappointingly only led to the approval of IFN-α and IL-2 as single agents [42], and GM-CSF, encoded in oncolytic herpes virus (T-VEC) [61], for the treatment of very few cancer indications. This evidence concerns the gene IL2 and cancer.